Opko Health, Inc.

OPKO Health maintains a conservative capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 3.61, indicating strong short-term liquidity coverage. The balance sheet holds $331.9 million in cash and equivalents against total liabilities of $652.2 million, with long-term debt limited to $2.0 million. However, the company carries significant non-debt obligations, including $246.6 million in senior secured royalty financing and $87.4 million in convertible notes, which are classified as long-term liabilities. The market capitalization stands at $1.09 billion, trading at a price-to-book ratio of 4.8 and an EV/Revenue multiple of 1.25.

Profitability remains negative, with a net loss of $54.8 million in Q1 2026, resulting in a return on equity of -18.7% and a return on assets of -12.2%. Gross profit was $45.8 million on revenue of $124.2 million, yielding a gross margin of approximately 36.8%, but operating expenses exceeded gross profit, leading to an operating loss of $51.0 million. Operating cash flow was negative $19.3 million for the quarter, reflecting the cash burn associated with ongoing operations and working capital changes.

Revenue generation is driven by its pharmaceutical and diagnostics segments, with significant exposure to international markets including Mexico, Chile, and Europe. The company holds $25.4 million in open foreign exchange forward contracts related to inventory purchases, highlighting currency risk in its international operations. Key products include Rayaldee, with sales returns and chargebacks noted in the financials, and diagnostic services provided through subsidiaries like GeneDx.

Growth trajectory is mixed, with Q1 2026 revenue of $124.2 million compared to a net loss of $67.6 million in the same period of 2025, showing a slight improvement in net loss magnitude. The company has been active in strategic transactions, including the sale of select assets of BioReference to Labcorp and the disposal of oncology-related assets. Capital expenditures were $1.8 million in Q1 2026, down from $3.2 million in the prior year, indicating a reduction in investment spending.

Risk factors include medium dilution risk due to the presence of convertible notes and stock options, as well as liquidity risk associated with negative operating cash flows. The company faces regulatory risks related to product approvals and reimbursement, particularly for new diagnostic and therapeutic products. Additionally, the company has settled litigation in the past, which may pose ongoing legal risks.

Recent events include the amendment of the collaboration agreement with Entera Bio and the continuation of the BARDA contract. Analyst sentiment is moderately positive, with a mean price target of $4.38 and a mean recommendation of 2.17, suggesting potential upside from the current price of $1.43. The company also reported a share repurchase of $4.8 million in Q1 2026, indicating some confidence in its valuation.

Analysts project 164% upside to a mean price target of $3.78, signaling strong market confidence in future recovery.

The company maintains a low leverage band with a debt-to-equity ratio of 0.27, ensuring financial stability.

A current ratio of 3.97 indicates robust short-term liquidity, effectively mitigating immediate solvency concerns for operations.

Long-term debt decreased to $2.3 million in FY2025, reflecting a deliberate strategy to reduce balance sheet obligations.

Liquidity risk is assessed as low, suggesting the company possesses sufficient resources to meet immediate financial demands.

The company faces high credit risk, raising significant concerns about its ability to manage debt and financial obligations.

Medium dilution risk exists, potentially eroding shareholder value through future equity issuances or conversion of debt instruments.

Revenue $124.2M; Operating income -$51.0M.

• ▍Revenue $124.2M
• ▍Operating income -$51.0M
• ▍Net margin -44.2%

Revenue $458.4M; Operating income -$79.1M.

• ▍Revenue $458.4M
• ▍Operating income -$79.1M
• ▍Net margin -42.4%

Revenue $306.8M; Operating income -$127.1M.

• ▍Revenue $306.8M
• ▍Operating income -$127.1M
• ▍Net margin -70.4%

Revenue $606.9M; Operating income -$117.4M.

• ▍Revenue $606.9M
• ▍Operating income -$117.4M
• ▍Net margin -37.2%

Revenue $151.7M; Net margin 14.3%.

• ▍Revenue $151.7M
• ▍Net margin 14.3%

Revenue $156.8M; Net margin -94.7%.

• ▍Revenue $156.8M
• ▍Net margin -94.7%

Revenue $150.0M; Net margin -45.1%.

• ▍Revenue $150.0M
• ▍Net margin -45.1%

Revenue $713.1M; Operating income -$152.1M.

• ▍Revenue $713.1M
• ▍Operating income -$152.1M
• ▍Net margin -7.5%